What was done?

A liaison pharmacist was assigned to the psychiatric intensive care unit (PICU) at Saint John of God Hospital to provide both a clinical pharmacy service including regular medication chart review and development of patient-centred clinical guidelines, and to provide medicines information and support directly to patients,



AL ST	
# hello my name is	
Caroline ;	
:5:	

		I EKS SUI	IE WEEKI	LY GROUP	TIMETAB	LE		
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	Saturday	Sunday	
6.00			WAKE UP CALL					
8.30-9.30	BREAKFAST - Medication Vital signs							
9am - 10am	Access to Elvira Garden							
THERAPY	MDI meeting	9.30-11.00 Psychology Group	Ward round	Mard round 11.00 Art Therapy	Ward round 11.30 MorningWalk	11.00-11.45 Gyni Session		
RECREATION	11.30 Morning Walk	11.30 Morning Walk	11.30 Morning Walk	11.30 Homing Walk		11.30 Morning Walk	11.70 Meening Walk	
12.30 - 14.00	LUNCH - Medication - Vital signs							
THERAPY	2.30-3.30 Occupational Therapy Group	2.30-3.30 Medication information group	2.30-3.30 Occupational Therapy Group	2.30-3.30 Psychology Group	Occupational Therapy 2.30-3.30	Activities at request	Visitors Walks and Activitie	
RECREATION	4.00-4.45 Garden	4.00-4.45 Gym	4.00-4.45 Garden	4.00-4.45 Gym	+ Gyen Session (+ Hassa sala that the finday		s at request	

Authors:

Caroline Hynes & **Dolores Keating Pharmacy** Department Saint John of God Hospital Stillorgan Co. Dublin

Patient-centred clinical pharmacy and medicines information service on a psychiatric intensive care unit

Why was it done?

Psychiatric intensive care is for patients who are in an acutely disturbed phase of a serious mental disorder. Psychotropic medicines play a pivotal role in the treatment of these disorders which is why the pharmacist is a key part of the patient care team. The introduction of a designated pharmacist to address not only the clinical needs of the PICU team but also the medicines information needs of the patient was essential to optimise patient outcomes. As positive experience with psychotropic medicine has implications for adherence and outcome, the role of the pharmacist in maintaining or improving this experience is of high importance.

3.2.26. All patients should have access to independent education and advice about medicines, preferably from a specialist mental health pharmacist in the PICU.

3.2.23. All prescriptions for medicines should be 'clinically screened' by a pharmacist to ensure suitability, safety, and that the relevant legal requirements are followed



How was it done?

The main obstacle to the introduction of this initiative was establishing a relationship with patients, as visible pharmacist interventions were new to patients on the PICU. In order to overcome this obstacle, the pharmacist was required to be present on the unit and regularly meet patients to enquire about their experience of taking medicine for their mental health and provide information as required.

 The pharmacist hosts a weekly medicines information group on the unit where; medicines are discussed openly, patients are provided with medicines information leaflets and medication charts detailing all of their current medicines and what they are for, and those taking antipsychotics are systematically assessed for side-effects using validated rating scales



- The pharmacist develops new patientcentred guidelines for use on the PICU, such as the guidelines on the pharmacological prevention and management of violence or
- The pharmacist carries out a regular clinical pharmacy review where medication charts are clinically assessed and any interventions are relayed to the relevant consultant psychiatrist and registrar



aggressive behaviour



What was achieved?

A liaison pharmacist was assigned to the psychiatric intensive care unit (PICU) at Saint John of God Hospital to provide both a clinical pharmacy service including regular medication chart review and development of patientcentred clinical guidelines, and to provide medicines information and support directly to patients.

What next....

Now that the pharmacist is a well-established member of the patient-care team on the psychiatric intensive care unit, future research will look at the impact this has on patient experience with psychotropic medicine and whether patient-centred pharmacist interventions improve attitude, adherence and ultimately outcome.

REFERENCES

- 1. National institute for health and care excellence. Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes March 2015. NICE clinical guideline 5, Available at: http://www.nice.org.uk/guidance/ng5/resources/medicines-optimisation-the-safe-and-effective-use-of-medicines-to-enable-the-best-possible-outcomes-51041805253 <a ccelebrates.
- 2. Picton C, Wright H. Medicines optimisation: helping patients to make the most of medicines. Good practice guidance for healthcare professionals in England. Royal pharmaceutical society.
- London; May 2013. Available at: http://www.rpharms.com/promoting-pharmacy-pdfs/helping-patients-make-the-most-of-their-medicines.pdf
 3. National association of psychiatric intensive care and low secure units. National Minimum Standards for Psychiatric Intensive Care in General Adult Services. Updated September 2014. Available

- 3. National association of psychiatric intensive Care and low sectore units. National vinimum standards for Psychiatric intensive Care in General Adult Services. Updated September 20 14. Available at http://napicu.org.uk/wp-content/uploads/2014/12/NMS-2014-final.pdf <a color by Content M. Conus P. Eide Petal. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. European Psychiatry 2004;19:415-22 5. Waddell L, Taylor M. Anew self-rating scale for detecting atypical or second-generation antipsychotic side effects. J Psychopharmacol 2008;22(3):238-43 6. Hynes C, Keating D, McWilliams S, Madigan K, Kinsella A, Maidment I, Feetam C, Drake RJ, Haddad PM, Gaughran F, Taylor M, Clarke M. Glasgow Antipsychotic Side-effects Scale for Clozapine-Development and validation of a clozapine-specific side-effects scale. Schizophr Res. 2015;168(1-2):505-13



